FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386524461> ?p ?o ?g. }

• W4386524461 abstract "Abstract Uterine serous carcinoma (USC) is a rare, biologically aggressive variant of endometrial cancer with a high recurrence rate and poor prognosis. HER2 overexpression (3+ positivity) by immunohistochemistry (IHC) and/or fluorescent in-situ hybridization (FISH) ERBB2 gene amplification is detected in approximately one-third of USC patients. Clinical trials incorporating trastuzumab with standard chemotherapy have recently demonstrated improved progression-free and overall survival in advanced-stage or recurrent USC that overexpresses HER2. However, a large number of USC patients eventually developed resistance to trastuzumab. Trastuzumab deruxtecan (T-DXd) is a novel HER2-directed antibody-drug conjugate with a topoisomerase I inhibitor payload recently approved by the Food and Drug Administration (FDA) for multiple tumor indications. Here, we investigated the in vitro and in vivo efficacy of T-DXd in primary USC cell lines and xenografts with different HER2 expression. T-DXd induced cell growth suppression in HER2-overexpressing cell lines in vitro, increased early and late apoptosis as assessed by annexin and propidium iodide staining, and, similarly to trastuzumab, T-DXd induced significant antibody-dependent cellular cytotoxicity (ADCC) in the presence of peripheral blood lymphocytes. While negligible activity was detected against USC cell lines with low HER2 expression, T-DXd demonstrated significant bystander killing against USC tumors with low/negligible HER2 when such cells were admixed with HER2 3+ tumor cells in vitro. T-DXd showed tumor growth suppression in in vivo USC PDX models that overexpress HER2 at 3+ levels, prolonging survival when compared to controls, with minimal toxicity. Future clinical trials are warranted in USC patients failing trastuzumab treatment." @default.
• W4386524461 created "2023-09-08" @default.
• W4386524461 creator A5006463532 @default.
• W4386524461 creator A5006468298 @default.
• W4386524461 creator A5010339370 @default.
• W4386524461 creator A5021257078 @default.
• W4386524461 creator A5026827320 @default.
• W4386524461 creator A5032849063 @default.
• W4386524461 creator A5035219534 @default.
• W4386524461 creator A5042405282 @default.
• W4386524461 creator A5042993069 @default.
• W4386524461 creator A5046373211 @default.
• W4386524461 creator A5046857977 @default.
• W4386524461 creator A5052476875 @default.
• W4386524461 creator A5053887305 @default.
• W4386524461 creator A5060188962 @default.
• W4386524461 creator A5060616502 @default.
• W4386524461 creator A5061191066 @default.
• W4386524461 creator A5061703014 @default.
• W4386524461 creator A5062471254 @default.
• W4386524461 creator A5077179116 @default.
• W4386524461 creator A5080849182 @default.
• W4386524461 creator A5081094174 @default.
• W4386524461 creator A5084210802 @default.
• W4386524461 date "2023-09-07" @default.
• W4386524461 modified "2023-09-29" @default.
• W4386524461 title "In vivo and in vitro efficacy of trastuzumab deruxtecan in uterine serous carcinoma" @default.
• W4386524461 doi "https://doi.org/10.1158/1535-7163.mct-23-0126" @default.
• W4386524461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37676984" @default.
• W4386524461 hasPublicationYear "2023" @default.
• W4386524461 type Work @default.
• W4386524461 citedByCount "0" @default.
• W4386524461 crossrefType "journal-article" @default.
• W4386524461 hasAuthorship W4386524461A5006463532 @default.
• W4386524461 hasAuthorship W4386524461A5006468298 @default.
• W4386524461 hasAuthorship W4386524461A5010339370 @default.
• W4386524461 hasAuthorship W4386524461A5021257078 @default.
• W4386524461 hasAuthorship W4386524461A5026827320 @default.
• W4386524461 hasAuthorship W4386524461A5032849063 @default.
• W4386524461 hasAuthorship W4386524461A5035219534 @default.
• W4386524461 hasAuthorship W4386524461A5042405282 @default.
• W4386524461 hasAuthorship W4386524461A5042993069 @default.
• W4386524461 hasAuthorship W4386524461A5046373211 @default.
• W4386524461 hasAuthorship W4386524461A5046857977 @default.
• W4386524461 hasAuthorship W4386524461A5052476875 @default.
• W4386524461 hasAuthorship W4386524461A5053887305 @default.
• W4386524461 hasAuthorship W4386524461A5060188962 @default.
• W4386524461 hasAuthorship W4386524461A5060616502 @default.
• W4386524461 hasAuthorship W4386524461A5061191066 @default.
• W4386524461 hasAuthorship W4386524461A5061703014 @default.
• W4386524461 hasAuthorship W4386524461A5062471254 @default.
• W4386524461 hasAuthorship W4386524461A5077179116 @default.
• W4386524461 hasAuthorship W4386524461A5080849182 @default.
• W4386524461 hasAuthorship W4386524461A5081094174 @default.
• W4386524461 hasAuthorship W4386524461A5084210802 @default.
• W4386524461 hasConcept C121608353 @default.
• W4386524461 hasConcept C126322002 @default.
• W4386524461 hasConcept C150903083 @default.
• W4386524461 hasConcept C159654299 @default.
• W4386524461 hasConcept C190283241 @default.
• W4386524461 hasConcept C203014093 @default.
• W4386524461 hasConcept C207001950 @default.
• W4386524461 hasConcept C2775934118 @default.
• W4386524461 hasConcept C2779786085 @default.
• W4386524461 hasConcept C31573885 @default.
• W4386524461 hasConcept C502942594 @default.
• W4386524461 hasConcept C530470458 @default.
• W4386524461 hasConcept C55493867 @default.
• W4386524461 hasConcept C71924100 @default.
• W4386524461 hasConcept C86803240 @default.
• W4386524461 hasConceptScore W4386524461C121608353 @default.
• W4386524461 hasConceptScore W4386524461C126322002 @default.
• W4386524461 hasConceptScore W4386524461C150903083 @default.
• W4386524461 hasConceptScore W4386524461C159654299 @default.
• W4386524461 hasConceptScore W4386524461C190283241 @default.
• W4386524461 hasConceptScore W4386524461C203014093 @default.
• W4386524461 hasConceptScore W4386524461C207001950 @default.
• W4386524461 hasConceptScore W4386524461C2775934118 @default.
• W4386524461 hasConceptScore W4386524461C2779786085 @default.
• W4386524461 hasConceptScore W4386524461C31573885 @default.
• W4386524461 hasConceptScore W4386524461C502942594 @default.
• W4386524461 hasConceptScore W4386524461C530470458 @default.
• W4386524461 hasConceptScore W4386524461C55493867 @default.
• W4386524461 hasConceptScore W4386524461C71924100 @default.
• W4386524461 hasConceptScore W4386524461C86803240 @default.
• W4386524461 hasLocation W43865244611 @default.
• W4386524461 hasLocation W43865244612 @default.
• W4386524461 hasOpenAccess W4386524461 @default.
• W4386524461 hasPrimaryLocation W43865244611 @default.
• W4386524461 hasRelatedWork W2003602567 @default.
• W4386524461 hasRelatedWork W2060924028 @default.
• W4386524461 hasRelatedWork W2328524531 @default.
• W4386524461 hasRelatedWork W2364368002 @default.
• W4386524461 hasRelatedWork W2365807994 @default.
• W4386524461 hasRelatedWork W2372638622 @default.
• W4386524461 hasRelatedWork W2372718837 @default.
• W4386524461 hasRelatedWork W2375889511 @default.
• W4386524461 hasRelatedWork W2393858372 @default.
• W4386524461 hasRelatedWork W2414946262 @default.
• W4386524461 isParatext "false" @default.

• next